Miller Investment Management LP Sells 10,280 Shares of Medtronic PLC $MDT

Miller Investment Management LP lessened its stake in shares of Medtronic PLC (NYSE:MDT) by 39.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 15,885 shares of the medical technology company’s stock after selling 10,280 shares during the period. Miller Investment Management LP’s holdings in Medtronic were worth $1,513,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of MDT. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic in the second quarter valued at $27,000. Corundum Trust Company INC bought a new position in Medtronic during the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. bought a new position in Medtronic during the 3rd quarter valued at about $29,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic in the 3rd quarter worth about $33,000. Finally, Tripletail Wealth Management LLC bought a new stake in Medtronic in the third quarter worth about $34,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Medtronic Price Performance

Shares of MDT stock opened at $98.54 on Tuesday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a fifty day simple moving average of $99.03 and a two-hundred day simple moving average of $96.80. The stock has a market capitalization of $126.33 billion, a price-to-earnings ratio of 27.45, a P/E/G ratio of 2.43 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the company posted $1.38 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is presently 79.11%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MDT. CICC Research began coverage on Medtronic in a research note on Friday, January 30th. They set an “outperform” rating on the stock. Leerink Partners dropped their price objective on Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a report on Wednesday, February 18th. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Citigroup began coverage on Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 target price for the company. Finally, The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $110.84.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).